Neutropenia, a common phenomenon during chemotherapy, seriously affects the therapeutic effect and patient prognosis, and clinicians usually use recombinant G‐CSF or GM‐CSF to induce neutropenia to increase patients’ white blood cell counts and enhance their immunity during chemotherapy in cancer patients [225]. This evidence concerns the gene CSF2 and neutropenia.